COMPASS THERAP. DL-,0001 Aktie Logo
US20454B1044
A2QF3P
CMPX

COMPASS THERAP. DL-,0001 Aktie

Chargement des cours...

Prévisions

L'objectif de cours moyen des analystes est de 4,25 € (+608,33 %). La médiane est de 3,64 € (+506,67 %).

Acheter
  16
Conserver
  1
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Compass Therapeutics reports positive phase 1 data for CTX-8371, stock remains under pressure

    Compass Therapeutics released phase 1 data on CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, showing three responses among 15 evaluable patients, including a >90% reduction in a case of triple-negative breast cancer. In the two highest dose cohorts (3.0 and 10.0 mg/kg) the overall response rate was 33% (2 of 6). No dose-limiting toxicities were observed; adverse events were mostly grade 1–2, with one asymptomatic grade 3 lipase elevation. The company has expanded cohorts for NSCLC, triple-negative breast cancer and Hodgkin lymphoma; additional data are expected in Q4 2026 and the results will be presented on May 30, 2026 at ASCO. Despite the clinical progress, the stock remains under pressure (market cap $326m, YTD loss 65% near a 52-week low) and investors are concerned about rapid cash burn. » Plus sur de.investing.com


  • Compass Therapeutics stock falls 80% after mixed COMPANION-002 data and approval concerns

    Compass Therapeutics’ shares plunged 80% after the Phase II/III COMPANION-002 study of tovecimig plus paclitaxel in cholangiocarcinoma produced mixed results. Progression-free survival showed high statistical significance, but the overall survival endpoint was not met. The company and analysts say the OS result was affected by frequent crossover of control patients into the tovecimig arm (54%), raising questions about the dataset’s suitability for FDA approval. A pre-BLA meeting in mid‑2026 is expected as the next key milestone, and investors anticipate continued volatility. » Plus sur de.investing.com


  • Compass Therapeutics: Tovecimig plus Paclitaxel meets secondary PFS endpoint in cholangiocarcinoma

    Compass Therapeutics reports that the combination of Tovecimig and Paclitaxel in the COMPANION-002 study met the secondary endpoint of progression-free survival (median PFS 4.7 vs. 2.6 months) with a hazard ratio of 0.44. The primary endpoint ORR was previously significant at 17.1% vs. 5.3%; overall survival did not reach significance, influenced by a 54% crossover in the control arm. Common adverse events included hypertension, fatigue and neutropenia; Compass plans a meeting with the FDA before a planned regulatory submission and will present the full data at a conference. » Plus sur de.investing.com


  • Compass Therapeutics rises after Craig‑Hallum buy recommendation

    Compass Therapeutics shares rose 3.1% after Craig‑Hallum initiated coverage with a buy rating and a $15.00 price target. The research firm praised the company’s BsAb approach and highlighted Tovecimig (PD‑1xVEGF‑A) as a potential second‑line agent for cholangiocarcinoma. Craig‑Hallum also pointed to promising early‑phase candidates such as CTX‑8371 and CTX‑10726 and sees further upside over the next 12–18 months as the company transitions to the commercial phase. » Plus sur de.investing.com


  • Compass Therapeutics reaches 52-week high at $5.86

    Shares of Compass Therapeutics climbed to a new 52-week high of $5.86 and are currently trading at $5.78. Over the past year the stock rose 249.4%, and year-to-date by about 300%, lifting the market capitalization to roughly $1.03 billion. The biotech is not yet profitable but shows strong liquidity with a current ratio of 17.82; analyst price targets range from $8 to $30, while the RSI points to a possible overbought condition. Compass plans to present preclinical data on its bispecific antibody candidate CTX-10726 at the annual meeting of the Society for Immunotherapy of Cancer, which is seen as a significant development step. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, COMPASS THERAP. DL-,0001 Aktie a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -23,99 M €
(EUR) septembre 2026
YoY
Chiffre d'affaires 0 -
Bénéfice brut 0 -
Bénéfice net -23,99 M 97,42 %
EBITDA -23,65 M 99,80 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
126,77 M €
Nombre d'actions
180,09 M
Plus haut/bas sur 52 semaines
6,26 € - 0,61 €
Dividendes Non
Bêta
0,91
Ratio P/E
-1,66
Ratio PEG
68,63
Ratio P/B
1,01
Ratio P/S
0,00

Profil de l'entreprise

Compass Therapeutics, Inc., une société biopharmaceutique au stade clinique axée sur l'oncologie, se consacre au développement de thérapeutiques à base d'anticorps destinées au traitement de diverses maladies humaines. Les candidats-médicaments de la société au stade clinique comprennent le CTX-009, un anticorps bispécifique à l'étude qui bloque les voies de signalisation Delta-like ligand 4/Notch et facteur de croissance de l'endothélium vasculaire A, lesquelles sont essentielles à l'angiogenèse et à la vascularisation tumorale ; ainsi que le CTX-471, un anticorps monoclonal IgG4 agoniste de CD137. Ses candidats-médicaments comprennent également le CTX-8371, un inhibiteur bispécifique ciblant PD-1 et PD-L1. La société a été fondée en 2014 et son siège social se situe à Boston, dans le Massachusetts.

Nom
COMPASS THERAP. DL-,0001 Aktie
PDG
Thomas J. Schuetz
Siège social Boston, ma
États-Unis
Site web
Industrie
Produits alimentaires
Introduction en bourse
05/04/2021
Employés 39

Symboles boursiers

Bourse Symbole
NASDAQ
CMPX
🍪

Parqet  utilise des cookies. En savoir plus